TrialHaematologica2026

Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study.

Mikkael A Sekeres et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.